Biggest winner from ENHANCE is AstraZeneca - Stocks - Options - Mutual Funds Article - mrk, sgp, azn

Make Money Submitting Links:

	Email to friend
	Print

Other writing by pharmaking

Tags

Investing, Stocks, Economy, Value, Income, Buffett, Passive, Dividends, Retirements, Recession, Apple, Dividend, Stock, Retirement, Real estate, Google, Market, Housing, Banks, Inflation, Stock market, Oil, China, Interest rates, Iphone.

Biggest winner from ENHANCE is AstraZeneca

Article Submitted by: pharmaking
Stocks - Options - Mutual Funds

Tags: Mrk, Sgp, Azn, Crestor, Vytorin, Zetia.

Buying AZN is the best way to play enhance if you didn't short MRK and SGP

Submitted: Mar 31, 2008 Views: 383 Comments: 1 Likes: 1

The money has already been made on shorting MRK and SGP, but there is still a good way to play the shake up in the statin market. Crestor should gain substanially in market share. It seems reasonable to think that they will pick up at least 20% of the zetia and vytorin defectors. That should be about 1 billion a year in new sales. In addition to all of this new business, AZN has released some very impressive data in the last 24 hours. Last night they announced that there large endpoint trial, Jupiter,showed benefit, and that it is being stopped early. While we don't know the exact numbers, this is huge news. Also , just a few minutes ago, the angiographic data from asteroid was released- showing that Crestor is the first drug to show net regression of stenosis.

So in summary, lots of good news in a stock which is near its 52 week low and paying a 5% dividend. I am putting all of the money I made yesterday shorting the other guys into this stock today.

Related Articles:

High dose statins lead to cancer. by pharmaking - Jul 23, 2007
MRK: Vaccines versus Vioxx by walt - Aug 26, 2007
Merck soars on new cholesterol drug news by pharmaking - Oct 11, 2007
Medtronic crashes by pharmaking - Oct 15, 2007
What to expect out of the American Heart Meeting by pharmaking - Nov 04, 2007
Cut Zetia in half, Cut Zetia Sales estimates in half. by pharmaking - Nov 04, 2007
What you get for your 2 and 30 by jsoc - Aug 17, 2007
Not too late to short MRK and SGP by pharmaking - Jan 27, 2008
Zetia and Vytorin- Where's the beef by pharmaking - Dec 02, 2007.

1

Email this story Email to someone | Print Content | Add to reading list

Comments Received:

drdellerdoc
(Unregistered)

Agree, AZN has moved to the front of the statin market any JUPITER results should open up a whole new potential market(normal LDL but high CRP levels). The pleiotropic effect may be even more important than the lipid lowering effect. Additionally, CORONA did show a significant reduction in rehospitalization rates in CHF pts. and expect GISSI-HF will do the same. Believe the immunomodulatory activity of statins in general has been under appreciated but awareness seems to be increasing.

Posted: Apr 2, 2008

© Copyright 2008 pharmaking All rights reserved. pharmaking has granted BestCashCow.com, LLC non-exclusive rights to display this work on Bestcashcow.com.

Financial products of all nature bear inherent risks and this website is not a financial advisory service; it is a forum for users to share and to compare notes and observations on financial publications. The website provides, free of charge, the technical and logistical apparatus and the medium for users to share and to publish financial information and to comment on publications. As such, the website’s operator can not and does not take responsibility for information, observations or opinions of any sort or nature provided by third parties with whom it is not affiliated who use the website to publish, to comment or as a means of solicitation. Users are specifically warned against following any advice related to specific instruments, including, but not limited to, equity securities, that may be provided by other users directly on this site or on web pages to which other users have provided links on this site. BestCashCow.com can not and does not check or verify the qualifications and credentials of users who publish or comment on this site or on linked pages. Users should seek personalized advice from qualified professionals regarding all personal financial issues and evaluate the risks and applicability to their own circumstances of each financial product discussed regardless of who the publisher is or purports to be. Should you, through your use of this site, identify an individual or organization purporting to offer personalized advice, you bear all responsibility to ensure that the individual or organization has the qualifications that they may represent on the website, and that their advice is appropriate for your circumstances. On certain webpages, BestCashCow.com provides information related to rates on US-based savings accounts, CDs, short-term government bonds, and other US cash equivalent securities, also free of charge to internet users for their independent use. The accuracy of this information is not guaranteed, and the information, like all other information on this website, should not be construed to provide investment advice, nor to endorse a financial product of any sort.

© 2007 BestCashCow.com, LLC. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy.